384 related articles for article (PubMed ID: 29447370)
41. An update on the management of gout.
Drug Ther Bull; 2018 Jan; 56(1):9-12. PubMed ID: 29326278
[TBL] [Abstract][Full Text] [Related]
42. Cohort study investigating gout flares and management in UK general practice.
Finnikin S; Mallen CD; Roddy E
BMC Prim Care; 2023 Nov; 24(1):246. PubMed ID: 37993770
[TBL] [Abstract][Full Text] [Related]
43. Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom.
Russell MD; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
Lancet Reg Health Eur; 2022 Jul; 18():100416. PubMed ID: 35814340
[TBL] [Abstract][Full Text] [Related]
44. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study.
Perez-Ruiz F; Carmona L; Yébenes MJ; Pascual E; de Miguel E; Ureña I; González-Gay MA;
J Clin Rheumatol; 2011 Oct; 17(7):349-55. PubMed ID: 21946457
[TBL] [Abstract][Full Text] [Related]
45. Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China.
Li QH; Dai L; Li ZX; Liu HJ; Zou CJ; Ou-Yang X; Lu M; Li T; Li YH; Mo YQ; Schumacher HR
Clin Rheumatol; 2013 Nov; 32(11):1633-40. PubMed ID: 23857664
[TBL] [Abstract][Full Text] [Related]
46. 2016 updated EULAR evidence-based recommendations for the management of gout.
Richette P; Doherty M; Pascual E; Barskova V; Becce F; Castañeda-Sanabria J; Coyfish M; Guillo S; Jansen TL; Janssens H; Lioté F; Mallen C; Nuki G; Perez-Ruiz F; Pimentao J; Punzi L; Pywell T; So A; Tausche AK; Uhlig T; Zavada J; Zhang W; Tubach F; Bardin T
Ann Rheum Dis; 2017 Jan; 76(1):29-42. PubMed ID: 27457514
[TBL] [Abstract][Full Text] [Related]
47. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
48. [Gout: an overview of available urate lowering therapies].
Richette P
Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
[TBL] [Abstract][Full Text] [Related]
49. Febuxostat in the management of gout: a cost-effectiveness analysis.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
[TBL] [Abstract][Full Text] [Related]
50. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).
Dalbeth N; Bardin T; Doherty M; Lioté F; Richette P; Saag KG; So AK; Stamp LK; Choi HK; Terkeltaub R
Nat Rev Rheumatol; 2017 Sep; 13(9):561-568. PubMed ID: 28794514
[TBL] [Abstract][Full Text] [Related]
51. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
52. A cross-sectional internet-based patient survey of the management strategies for gout.
Singh JA; Shah N; Edwards NL
BMC Complement Altern Med; 2016 Mar; 16():90. PubMed ID: 26931313
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of a urate lowering regimen in primary gout.
Bailén R; González Senac NM; López MM; Llena ML; Migoya M; Rodríguez MT; de Miguel E; Torres RJ; Puig JG
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):174-80. PubMed ID: 24940666
[TBL] [Abstract][Full Text] [Related]
54. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Whelton A; MacDonald PA; Chefo S; Gunawardhana L
Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
[TBL] [Abstract][Full Text] [Related]
55. Global patterns of treat-to-serum urate target care for gout: Systematic review and meta-analysis.
Son CN; Stewart S; Su I; Mihov B; Gamble G; Dalbeth N
Semin Arthritis Rheum; 2021 Aug; 51(4):677-684. PubMed ID: 34139520
[TBL] [Abstract][Full Text] [Related]
56. Italian Society of Rheumatology recommendations for the management of gout.
Manara M; Bortoluzzi A; Favero M; Prevete I; Scirè CA; Bianchi G; Borghi C; Cimmino MA; D'Avola GM; Desideri G; Di Giacinto G; Govoni M; Grassi W; Lombardi A; Marangella M; Matucci Cerinic M; Medea G; Ramonda R; Spadaro A; Punzi L; Minisola G
Reumatismo; 2013 Mar; 65(1):4-21. PubMed ID: 23550256
[TBL] [Abstract][Full Text] [Related]
57. Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study.
Abhishek A; Jenkins W; La-Crette J; Fernandes G; Doherty M
Rheumatology (Oxford); 2017 Apr; 56(4):529-533. PubMed ID: 28082620
[TBL] [Abstract][Full Text] [Related]
58. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
59. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
60. Gout treatment: survey of Brazilian rheumatology residents.
Amorim RBC; Vargas-Santos AB; Pereira LR; Coutinho ESF; da Rocha Castelar-Pinheiro G
Clin Rheumatol; 2017 May; 36(5):1179-1188. PubMed ID: 28101833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
